局限性前列腺癌最大雄激素阻断治疗的雄激素剥夺治疗时间。

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer.

机构信息

Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.

出版信息

BMC Urol. 2011 May 14;11:7. doi: 10.1186/1471-2490-11-7.

DOI:10.1186/1471-2490-11-7

PMID:21569574

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3116482/

Abstract

BACKGROUND

Primary androgen deprivation therapy (ADT) is a treatment option not only for advanced but also for localized prostate cancer. However, the appropriate duration for primary ADT for localized prostate cancer has not been defined and few studies have addressed this issue. In this study, we aimed to determine the appropriate duration of ADT for localized prostate cancer.

METHODS

Sixty-eight consecutive patients with localized prostate cancer who underwent a prostatectomy following neoadjuvant ADT were retrospectively reviewed. Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.

RESULTS

Of the 68 males, 24 (35.3%) were classified as pT0. The median duration of neoadjuvant ADT in the pT0 and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). The duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery was longer in the pT0 group than that in the non-pT0 group (median 5 months against 3 months, p = 0.011). pT0 was achieved in 5 of 6 patients (83.3%) who received ADT for ≥10 months after PSA reached < 0.2 ng/ml. No other clinical characteristics predicted conversion to pT0.

CONCLUSIONS

Continuous ADT for ≥10 months after PSA reached < 0.2 ng/ml induced serious prostate cancer cell damage in most patients (> 80%) and may be sufficient to treat localized prostate cancer.

摘要

背景

初级雄激素剥夺疗法（ADT）不仅是治疗晚期前列腺癌的选择，也是治疗局部前列腺癌的选择。然而，尚未确定局部前列腺癌初级 ADT 的适当持续时间，并且很少有研究涉及这个问题。在这项研究中，我们旨在确定局部前列腺癌的适当 ADT 持续时间。

方法

回顾性分析了 68 例接受新辅助 ADT 后行前列腺切除术的局部前列腺癌连续患者。研究了与被视为严重癌细胞损伤或消除的 pT0 相关的因素。

结果

在 68 名男性中，有 24 名（35.3%）被分类为 pT0。pT0 组和非 pT0 组新辅助 ADT 的中位持续时间分别为 9 个月和 7.5 个月（p=0.022）。PSA 降至<0.2ng/ml 后至手术时新辅助 ADT 的持续时间在 pT0 组比非 pT0 组长（中位数 5 个月对 3 个月，p=0.011）。在 PSA 降至<0.2ng/ml 后接受 ADT 治疗≥10 个月的 6 例患者中的 5 例（83.3%）达到 pT0。没有其他临床特征预测转化为 pT0。